Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives

Abstract

Concizumab is a monoclonal, humanized IgG4 antibody specific for the Kunitz-2 domain of Tissue Factor Pathway Inhibitor (TFPI). Preclinical studies in vitro or on animal models and in vivo have demonstrated the ability of concizumab to restore thrombin generation, promoting the establishment of a procoagulant action; all these results were subsequently confirmed in the studies of EXPLORER program. Concizumab may represent a new opportunity for the treatment of persons with hemophilia, so there is much anticipation for the results of the ongoing trials still. This review retraces all the studies on concizumab published to date, with a brief discussion about the patient’ perspectives.

Keywords:

• hemophilia
• concizumab
• anti-TFPI antibodies
• new hemophilia treatments

Acknowledgment

I thank Prof. Pier Mannuccio Mannucci who provided insight and expertise that improved the manuscript.

Disclosure

S. Pasca has received fees from Bayer, Kedrion, Roche, Baxalta, Novo Nordisk, CSL Behring, Pfizer, Sobi, and Takeda. The author reports no other conflicts of interest in this work.